Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
47.48
+0.01 (0.02%)
At close: Mar 3, 2026, 4:00 PM EST
47.50
+0.02 (0.04%)
Pre-market: Mar 4, 2026, 8:48 AM EST
Royalty Pharma Revenue
In the year 2025, Royalty Pharma had annual revenue of $2.38B with 5.06% growth. Royalty Pharma had revenue of $621.99M in the quarter ending December 31, 2025, with 4.78% growth.
Revenue (ttm)
$2.38B
Revenue Growth
+5.06%
P/S Ratio
11.52
Revenue / Employee
$23,781,930
Employees
100
Market Cap
27.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.38B | 114.62M | 5.06% |
| Dec 31, 2024 | 2.26B | -90.98M | -3.86% |
| Dec 31, 2023 | 2.35B | 117.34M | 5.24% |
| Dec 31, 2022 | 2.24B | -52.25M | -2.28% |
| Dec 31, 2021 | 2.29B | 167.11M | 7.87% |
| Dec 31, 2020 | 2.12B | 308.10M | 16.98% |
| Dec 31, 2019 | 1.81B | 19.36M | 1.08% |
| Dec 31, 2018 | 1.79B | 196.96M | 12.33% |
| Dec 31, 2017 | 1.60B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 5.34B |
| Incyte | 5.14B |
| argenx SE | 4.25B |
| Genmab | 3.72B |
| Alnylam Pharmaceuticals | 3.71B |
| BioNTech SE | 3.70B |
| Moderna | 1.94B |
| Ascendis Pharma | 845.52M |
RPRX News
- 17 hours ago - Royalty Pharma plc (RPRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 2 days ago - Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform - GlobeNewsWire
- 2 days ago - Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing - GlobeNewsWire
- 5 days ago - Royalty Pharma to Present at TD Cowen's 46th Annual Health Care Conference - GlobeNewsWire
- 16 days ago - Royalty Pharma: 2025 Financial Performance And Strategic Outlook - Seeking Alpha
- 19 days ago - Royalty Pharma: Strong Execution And Visible Pipeline Support Our Buy View - Seeking Alpha
- 20 days ago - Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Royalty Pharma Reports Q4 and Full Year 2025 Results - GlobeNewsWire